Trials / Completed
CompletedNCT01322594
A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease
A Phase 1, Single Ascending Dose Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
Phase I study to evaluate the safety and tolerability of single ascending intravenous doses of MEDI2338 in subjects with stable, mild to moderate chronic obstructive pulmonary disease (COPD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MEDI2338 | MEDI2338 single intravenous (IV) dose (lowest dose) |
| BIOLOGICAL | MEDI2338 | MEDI2338 single IV dose (next highest dose) |
| BIOLOGICAL | MEDI2338 | MEDI2338 single IV dose (next highest dose) |
| BIOLOGICAL | MEDI2338 | MEDI2338 single IV dose (next highest dose) |
| BIOLOGICAL | MEDI2338 | MEDI2338 single IV dose (highest dose) |
| OTHER | Placebo | Placebo single IV dose |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2011-11-01
- Completion
- 2011-12-01
- First posted
- 2011-03-24
- Last updated
- 2013-10-23
- Results posted
- 2013-10-23
Locations
4 sites across 2 countries: South Africa, United Kingdom
Source: ClinicalTrials.gov record NCT01322594. Inclusion in this directory is not an endorsement.